MDXH

BEARISH

$2.14 Live

MDxHealth SA · NASDAQ

Target $7.4 (+245.8%)

$1.51 52W Range $5.33

MDXH MDxHealth SA - Fundamental Analysis

BEARISH

Console Chart News

MDXH Stock | Fundamental Analysis & Investment Insights

NASDAQ • Healthcare • Diagnostics & Research

Current Price Live

$2.14

Analyst Target

$7.4

+245.8% Upside

52W High

$5.33

52W Low

$1.51

Overview AI Snowflake Price Valuation Profitability Growth Health Statements Peers Insiders

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 14, 2026

Market cap

$109.92M

P/E

N/A

ROE

-2440.4%

Profit margin

-31.1%

Debt/Equity

N/A

Dividend yield

N/A

AI Analysis

AI-powered fundamental assessment

Confidence

95%

MDXH exhibits severe financial distress, highlighted by a critical Piotroski F-Score of 1/9 and a negative Price-to-Book ratio of -9.30, indicating negative shareholder equity. While the company maintains a strong gross margin (64.55%) and positive revenue growth (~19%), these are completely offset by catastrophic ROE (-2440%) and a consistent track record of missing earnings estimates (0/4 beats in the last year). The technical trend is purely bearish, and the lack of a valid Altman Z-Score combined with poor liquidity ratios suggests a high risk of insolvency.

Key Strengths

Strong Gross Margin of 64.55%

Consistent YoY and Q/Q Revenue Growth (~19%)

Significant gap between current price and analyst target price ($7.40)

Low Price-to-Sales ratio (1.02)

Positive revenue trajectory in a specialized healthcare niche

Key Risks

Negative Shareholder Equity (P/B of -9.30)

Extreme operational inefficiency (ROE of -2440.41%)

Chronic earnings misses with an average surprise of -31.46%

Weak liquidity with a Quick Ratio below 1.0 (0.89)

Severe long-term value destruction (5Y Change: -82.2%)

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall

Weak

Value

Future

Past

Health

Dividend

AI Verdict

High Risk / Distressed

Key drivers: Negative Equity, Piotroski F-Score 1/9, Consistent EPS misses, Bearish technicals

Confidence

90%

Value

10/100

P/B of -9.30 indicates the company's liabilities exceed its assets.

Positives

Low P/S ratio

Watchpoints

Negative P/B ratio
No Graham Number possible due to negative earnings

Future

40/100

Growth is present but not translating to bottom-line viability.

Positives

Revenue growth of 19.4%

Watchpoints

Negative forward P/E
Failure to convert revenue growth into profit

Past

10/100

Long-term trend shows systemic failure to meet financial expectations.

Positives

No standout positives identified.

Watchpoints

5Y return of -82.2%
Consistent quarterly earnings misses

Health

5/100

F-Score of 1/9 is a strong deterministic signal of financial weakness.

Positives

Current ratio slightly above 1.0

Watchpoints

Piotroski F-Score 1/9
Negative ROE

Dividend

0/100

Dividend strength is 0/100.

Positives

No standout positives identified.

Watchpoints

No dividend paid
No capacity for dividends

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price

$2.14

Analyst Target

$7.4

Upside/Downside

+245.8%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for MDXH and closest competitors.

Updated 2026-04-13

Company	5Y	3Y	1Y	6M	1M	1W
MDXH MDxHealth SA Primary	-82.2%	-35.5%	+37.2%	-49.0%	-33.1%	+4.4%
DH Definitive Healthcare Corp. Peer	-97.5%	-89.8%	-57.4%	-66.5%	-13.7%	-13.0%
FONR FONAR Corporation Peer	+3.3%	+15.4%	+48.2%	+20.1%	+0.7%	+0.1%
IMDX Insight Molecular Diagnostics Inc. Peer	-97.0%	-53.0%	+9.3%	-18.5%	-39.6%	-15.7%
KZIA Kazia Therapeutics Limited Peer	-98.5%	-84.8%	+141.6%	+26.4%	+8.8%	+20.2%

MDX

MDxHealth SA

Primary

-82.2%

-35.5%

+37.2%

-49.0%

-33.1%

+4.4%

Definitive Healthcare Corp.

Peer

-97.5%

-89.8%

-57.4%

-66.5%

-13.7%

-13.0%

FON

FONAR Corporation

Peer

+3.3%

+15.4%

+48.2%

+20.1%

+0.7%

+0.1%

IMD

Insight Molecular Diagnostics Inc.

Peer

-97.0%

-53.0%

+9.3%

-18.5%

-39.6%

-15.7%

KZI

Kazia Therapeutics Limited

Peer

-98.5%

-84.8%

+141.6%

+26.4%

+8.8%

+20.2%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

N/A

-16.46

N/A

-9.3

1.02

1.55

-23.71

$109.92M

Profitability

Profit margins and return metrics

Profit Margin -31.07%

Operating Margin -17.81%

Gross Margin 64.55%

ROE -2440.41%

ROA -5.9%

Growth

Revenue and earnings growth rates

Revenue Growth +19.4%

Earnings Growth N/A

Q/Q Revenue Growth +19.43%

Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity

N/A

Current Ratio

1.08

Good

Quick Ratio

0.89

Poor

Cash/Share

$0.57

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue

$0.0B

Gross Margin

63.2%

Op. Margin

-21.1%

Net Margin

-30.2%

Total Assets

$0.1B

Liabilities

$0.2B

Equity

$-0.0B

Debt/Equity

-13.23x

Operating CF

$0.0B

CapEx

$-0.0B

Free Cash Flow

$0.0B

FCF Yield

86%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-05-14

$N/A

2026-02-26

$-0.17

-33.3% surprise

2025-11-12

$-0.16

-48.1% surprise

2025-08-14

$-0.14

-12.9% surprise

Healthcare Sector Comparison

Comparing MDXH against 319 companies in the Healthcare sector (20 bullish, 107 neutral, 192 bearish)

Return on Equity (ROE)

-2440.41%

This Stock

-86.0%

Sector Avg

+2737.8% (Excellent)

Profit Margin

-31.07%

This Stock

-11.76%

Sector Avg

+164.2% (Superior)

Revenue Growth

19.4%

This Stock

90.15%

Sector Avg

-78.5% (Slower)

Current Ratio

1.08

This Stock

3.67

Sector Avg

-70.6% (Weaker)

Similar Companies

Peer comparison within the same industry

Company	AI Rating	Market Cap	P/E	ROE	Profit Margin	Price
MDXH MDxHealth SA	BEARISH	$109.92M	-	-2440.4%	-31.1%	$2.14
DH Definitive Healthcare Corp.	NEUTRAL	$111.79M	-	-40.4%	-57.5%	$1.07	Compare
FONR FONAR Corporation	NEUTRAL	$117.26M	16.18	6.0%	7.1%	$18.61	Compare
IMDX Insight Molecular Diagnostics Inc.	BEARISH	$101.97M	-	-%	-%	$3.17	Compare
KZIA Kazia Therapeutics Limited	NEUTRAL	$100.79M	-	-106.9%	-%	$8.82	Compare

MDXH MDxHealth SA

BEARISH

Mkt Cap

$110M

P/E

ROE

-2440.4%

Price

$2.14

Compare with MDXH

FONR FONAR Corporation

Compare with MDXH

Compare with MDXH

Compare with MDXH

Wall Street Analysts

Professional analyst ratings and price targets

Consensus

NONE

5 analysts

BTIG

2025-12-23

reit

Buy Buy

TD Cowen

2025-11-13

Maintains

Buy Buy

Lake Street

2025-11-13

Maintains

Buy Buy

BTIG

2025-11-13

Maintains

Buy Buy

Past News Coverage

Recent headlines mentioning MDXH from our newsroom.

Newest → oldest

Back to All Stocks

TradingGPT V2 Copilot

Fundamentals • Valuation • Risk

Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends

MDXH

MDXH MDxHealth SA - Fundamental Analysis

At a glance

AI Analysis

Key Strengths

Key Risks

Performance Snowflake

Stock Price & Analyst Targets

Multi-Horizon Performance vs Peers

Historical Performance Trends

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Valuation Metrics

Profitability

Growth

Financial Health

Financial Statement Flow

Quarterly Earnings History

Healthcare Sector Comparison

Similar Companies

Wall Street Analysts

Past News Coverage

Wait — Don't Miss Out!